About the study

The purpose of this study is to evaluate the safety and tolerability of AB521 when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Male or female participants >= 18 years of age (or at least the age that is regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent form (ICF).
2. Disease-specific criteria for dose escalation: Participants may have any pathologically confirmed solid tumor type where no other treatment options are available.
3. Disease-specific criteria for dose-expansion: Histologically confirmed ccRCC, must have received prior treatment in the metastatic setting (either individually or in combination) with an anti-programmed cell death protein 1 (anti-PD-1) therapy and a tyrosine kinase inhibitor (TKI), and no prior treatment with an hypoxia inducible factor (HIF)-2 alpha (α)-targeting therapy.
4. Must have at least one measurable lesion per RECIST guidance.
5. Other, more specific inclusion criteria are defined in the protocol. Key

Exclusion criteria

1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product.
2. Underlying medical conditions that, in the investigator's judgment, will make the administration of investigational product hazardous (eg, interstitial lung disease, active infections requiring antibiotics, recent hospitalizations with unresolved symptoms) or obscure the interpretation of toxicity determination or AEs.
3. History of trauma or major surgery within 28 days prior to the first dose of investigational product.
4. For monotherapy dose expansion: prior treatment with an HIF-2α inhibitor.
5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.